Phase I Endovenous Administration of Oncolytic Adenovirus ICOVIR-5 in Patients With Advanced or Metastatic Melanoma
The investigators will evaluate the safety of a single endovenous infusion of ICOVIR5 in adults with locally advanced and metastatic melanoma. ICOVIR5 consists in a conditionally replicative or oncolytic adenovirus.
Locally Advanced or Metastatic Melanoma
BIOLOGICAL: ICOVIR-5
Maximum tolerated dose, The highest dose where less than two out of three or six patients suffered dose limiting toxicity., 4 weeks
Recommended dose, 4 weeks|Anti-tumour activity, 4 weeks
Viral pharmacokinetics, Viremia at 0 minutes, 30 minutes, 1 hour, 2 hours, 4 hours, 6 hours and 24 hours after endovenous injection., 1 day|Viral pharmacodynamics, Virus presence in tumors at day 5 post-administration., 5 days
The investigators will evaluate the safety of a single endovenous infusion of ICOVIR5 in adults with locally advanced and metastatic melanoma. ICOVIR5 consists in a conditionally replicative or oncolytic adenovirus.